Roflupram

Roflupram is a selective, orally active and brain-penetrant PDE4 inhibitor, with an IC50 of 26.2 nM for core catalytic domains of human PDE4. Roflupram can reverse cognitive deficits and reduce the production of pro-inflammatory factors[1][2].

Product Specifications

CAS Number

[1093412-18-0]

Product Name Alternative

MitoQ (mesylate); MitoQ10 (mesylate)

UNSPSC

12352005

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/roflupram.html

Purity

99.45

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(CC(C1=CC=C(C(OC2COCC2)=C1)OC(F)F)=O)C

Molecular Formula

C16H20F2O4

Molecular Weight

314.32

References & Citations

[1]Li D, et, al. Roflupram, a novel phosphodiesterase 4 inhibitor, inhibits lipopolysaccharide-induced neuroinflammatory responses through activation of the AMPK/Sirt1 pathway. Int Immunopharmacol. 2021 Jan;90:107176. |[2]You T, et, al. Roflupram, a Phosphodiesterase 4 Inhibitior, Suppresses Inflammasome Activation through Autophagy in Microglial Cells. ACS Chem Neurosci. 2017 Nov 15;8 (11) :2381-2392.